Investors bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Monday. $218.52 million flowed into the stock on the tick-up and $120.02 million flowed out of the stock on the tick-down, for a money net flow of $98.50 million into the stock. Of all companies tracked, Johnson & Johnson had the 12th highest net in-flow for the day. Johnson & Johnson traded down ($0.40) for the day and closed at $132.00
JNJ has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research note on Tuesday, November 20th. HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, October 14th. ValuEngine upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Thursday, December 13th. Finally, Morgan Stanley reduced their price target on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $142.20.
The company has a market capitalization of $355.22 billion, a P/E ratio of 16.14, a P/E/G ratio of 2.11 and a beta of 0.68. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th will be given a dividend of $0.90 per share. The ex-dividend date is Monday, February 25th. This represents a $3.60 annualized dividend and a yield of 2.73%. Johnson & Johnson’s dividend payout ratio (DPR) is 44.01%.
Johnson & Johnson announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 17th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the company to purchase up to 1.5% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its stock is undervalued.
In related news, CEO Alex Gorsky sold 264,465 shares of the business’s stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $145.96, for a total transaction of $38,601,311.40. Following the completion of the sale, the chief executive officer now directly owns 481,254 shares in the company, valued at $70,243,833.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael E. Sneed sold 30,943 shares of the business’s stock in a transaction that occurred on Friday, November 23rd. The shares were sold at an average price of $142.46, for a total transaction of $4,408,139.78. Following the sale, the executive vice president now owns 70,817 shares of the company’s stock, valued at $10,088,589.82. The disclosure for this sale can be found here. Insiders have sold 465,746 shares of company stock valued at $67,951,916 over the last 90 days. 0.22% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in JNJ. Cambridge Advisors Inc. lifted its holdings in Johnson & Johnson by 0.3% during the fourth quarter. Cambridge Advisors Inc. now owns 22,436 shares of the company’s stock valued at $2,895,000 after purchasing an additional 78 shares in the last quarter. Stuart Chaussee & Associates Inc. lifted its holdings in Johnson & Johnson by 20.7% during the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 80 shares in the last quarter. Deane Retirement Strategies Inc. lifted its holdings in Johnson & Johnson by 0.7% during the fourth quarter. Deane Retirement Strategies Inc. now owns 12,458 shares of the company’s stock valued at $1,608,000 after purchasing an additional 82 shares in the last quarter. Burt Wealth Advisors lifted its holdings in Johnson & Johnson by 0.6% during the fourth quarter. Burt Wealth Advisors now owns 12,898 shares of the company’s stock valued at $1,665,000 after purchasing an additional 82 shares in the last quarter. Finally, Timber Creek Capital Management LLC lifted its holdings in Johnson & Johnson by 8.7% during the fourth quarter. Timber Creek Capital Management LLC now owns 1,035 shares of the company’s stock valued at $133,000 after purchasing an additional 83 shares in the last quarter. Institutional investors own 68.98% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Traders Buy Shares of Johnson & Johnson (JNJ) on Weakness” was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://dakotafinancialnews.com/2019/02/11/traders-buy-shares-of-johnson-johnson-jnj-on-weakness.html.
Johnson & Johnson Company Profile (NYSE:JNJ)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.